CEUS: Contrast-Enhanced Ultrasound for Perfusion Assessment and Lesion Characterization

Contrast-enhanced ultrasound (CEUS) uses microbubble agents to map perfusion in real time, aiding diagnosis of liver, renal and vascular lesions without radiation or nephrotoxicity.

Contrast-enhanced ultrasound, abbreviated CEUS, is a technique that uses intravenous microbubble agents to turn conventional ultrasound into a dynamic, real-time perfusion study. Unlike the iodinated contrast used in computed tomography (CT) or the gadolinium-based agents used in magnetic resonance imaging (MRI), CEUS microbubbles consist of an inert gas core (typically sulfur hexafluoride or a perfluorocarbon) encased in a lipid or protein shell, with a diameter close to that of a red blood cell.

This size keeps microbubbles strictly intravascular, acting as a pure blood-pool tracer — unlike CT or MRI contrast, they do not diffuse into the interstitium. The result is real-time perfusion imaging with far higher temporal resolution than the fixed arterial, portal and delayed phases captured on CT or MRI, allowing continuous, frame-by-frame observation of a lesion's wash-in and wash-out.

Safety: no nephrotoxicity, no ionizing radiation

Because microbubbles are cleared through the lungs by exhalation rather than by the kidneys, CEUS carries none of the contrast-induced nephropathy risk associated with iodinated CT agents, nor the risk of nephrogenic systemic fibrosis linked to gadolinium in patients with severe renal impairment. There is also no ionizing radiation exposure, making the technique attractive for serial studies, pediatric patients, pregnancy (when indicated) and patients who need repeated reassessment over time, such as in oncologic follow-up.

Serious adverse reactions are rare. Pharmacovigilance studies in large cohorts report a very low rate of anaphylactoid events, lower than that observed with iodinated CT contrast, which allows CEUS to be used even in patients with a history of allergic reaction to those agents. Even so, as with any contrast agent, facilities offering CEUS must be equipped to manage allergic reactions.

Principles of perfusion assessment

After intravenous bolus injection, the operator observes the lesion continuously in low mechanical-index contrast mode, recording the enhancement pattern across three classic liver phases: arterial (roughly 10 to 30 seconds after injection), portal venous (30 to 120 seconds) and late/delayed (from 120 seconds up to about 4 to 6 minutes, depending on the agent). The analysis combines the timing of enhancement onset, its intensity relative to adjacent parenchyma and, most importantly, the pattern and timing of washout, usually the most discriminating feature between benign and malignant lesions.

In general, malignant lesions tend to show earlier and more marked washout, while benign lesions retain enhancement closer to or equal to the surrounding parenchyma in the late phase. This logic underlies the CEUS LI-RADS system (Liver Imaging Reporting and Data System), developed by the American College of Radiology specifically to standardize characterization of liver nodules in patients at risk for hepatocellular carcinoma (HCC), analogous to CT/MRI LI-RADS but with its own criteria adapted to microbubble kinetics.

Characterization of focal liver lesions

The liver is by far the most established CEUS application. Hemangiomas typically show peripheral globular nodular enhancement in the arterial phase with progressive centripetal fill-in and persistent enhancement in the late phases. Focal nodular hyperplasia (FNH) classically shows fast, intense arterial enhancement with a spoke-wheel pattern (radiating central vessels) and no washout in the late phase, reflecting its benign hepatocellular origin and functioning Kupffer cells. HCC tends to show arterial hyperenhancement followed by washout in the portal or late phase, while liver metastases typically show rim-like arterial enhancement with early, marked washout already in the portal phase.

A 2024 meta-analysis evaluating modified CEUS LI-RADS with Sonazoid (a second-generation agent with specific hepatosplenic uptake in the Kupffer phase) for HCC diagnosis found a pooled sensitivity of 0.77 (95% CI: 0.70–0.82), specificity of 0.88 (95% CI: 0.83–0.92) and an area under the ROC curve of 0.91 (95% CI: 0.88–0.93) for the LR-5 category. The authors noted that while sensitivity was reasonable, Kupffer-phase defects perform better as an ancillary finding than as a standalone criterion for definitive diagnosis. Another systematic review, published in Acta Radiologica in 2023, evaluating CEUS LR-5 more broadly, likewise confirmed satisfactory specificity for HCC diagnosis in high-risk patients.

One critical difference from CT/MRI LI-RADS deserves emphasis: on CEUS, cholangiocarcinoma and some poorly differentiated HCCs can show very early (within the first 60 seconds) and marked washout, a pattern that led to the LR-M category (probably malignant, not HCC-specific), specifically to flag that this enhancement pattern raises suspicion for a non-HCC malignancy and may warrant biopsy even in a cirrhotic liver.

Renal lesions: complex cysts and solid nodules

In the kidney, CEUS has a well-established role in distinguishing complex cystic from solid masses, and is particularly useful for applying the Bosniak classification to indeterminate lesions identified on CT or MRI. The literature shows CEUS can be more sensitive than conventional ultrasound and, in some scenarios, comparable to or better than CT for detecting thin septa, subtle wall thickening and enhancement of solid components, since microbubble enhancement is purely intravascular and is not subject to the partial-volume effect that can mask subtle enhancement on CT.

Precisely because of this high sensitivity, recent reviews warn of an upstaging risk when Bosniak criteria designed for CT/MRI are applied directly to CEUS: septa and enhancement too subtle to see except with the microbubbles' temporal resolution can artificially raise a lesion's category. For this reason, proposals for a CEUS-specific Bosniak system have been discussed in the literature, aiming to recalibrate septal/wall thickening and enhancement thresholds for this modality, reducing unnecessary biopsies or surgeries for lesions that in practice carry low malignancy risk.

Prostate applications: evidence still maturing

In the prostate, CEUS has been studied mainly as a guide for targeted biopsy, based on the principle that clinically significant cancer tends to show neoangiogenesis and therefore earlier, more intense enhancement than normal prostatic tissue. A 2022/2023 meta-analysis comparing CEUS-targeted biopsy versus conventional systematic transrectal ultrasound-guided biopsy found significantly higher pooled sensitivity for CEUS (odds ratio of approximately 1.77), with an even more marked advantage in the PSA 4 to 10 ng/mL range (odds ratio around 2.66) and higher detection of clinically significant disease (Gleason score greater than 6).

Even so, it is important to be honest about the evidence level: most prostate CEUS studies have moderate sample sizes, come from specialized centers, and often predate the widespread adoption of multiparametric MRI and the PI-RADS system, which today is the reference standard for screening clinically significant prostate cancer in most services. Prostate CEUS therefore remains a complementary tool, used mainly in centers with specific expertise, rather than an established alternative to multiparametric MRI in general clinical practice.

Vascular applications: endoleaks and carotid plaque

After endovascular aortic aneurysm repair (EVAR), CEUS is a well-established tool for detecting endoleaks (blood flow leaking into the aneurysm sac outside the stent graft), allowing the type of endoleak to be characterized by the origin and direction of flow observed in real time. Meta-analyses accumulated over the past decade, including systematic reviews comparing CEUS with CT angiography as the reference standard, show consistently high diagnostic performance of CEUS for endoleak detection, with the added advantage of avoiding repeated radiation and iodinated contrast exposure in patients who need surveillance for many years after the procedure.

In carotid disease, CEUS allows assessment of intraplaque neovascularization, a marker of atherosclerotic plaque instability and vulnerability associated with higher cerebrovascular event risk. A 2023 narrative review describes a sensitivity of 94% and a positive predictive value of 87% for CEUS in identifying histologically vulnerable plaques, using visual grading systems (0 to 3) that correlate the degree of intraplaque enhancement with increased cardiovascular risk and higher recurrence of ischemic events in patients with prior stroke or TIA, although the authors themselves acknowledge the need for larger prospective studies for broad clinical validation.

Oncologic follow-up and treatment response

One of the most valuable oncologic applications of CEUS is assessing response to loco-regional liver therapies, such as radiofrequency or microwave ablation and transarterial chemoembolization (TACE). A 2025 meta-analysis evaluating CEUS performance in predicting therapeutic response after radiofrequency ablation in HCC patients (13 studies, 802 patients, 964 lesions) found a pooled sensitivity of 0.88 (95% CI: 0.80–0.93) and specificity of 0.98 (95% CI: 0.96–0.99) for detecting residual or recurrent tumor, with the authors concluding the method shows excellent diagnostic performance and recommending its incorporation into post-ablation follow-up algorithms.

This ability to detect early persistence of blood flow within a treated area — often before morphological changes become apparent on CT — allows for earlier reintervention in cases of incomplete ablation, while also reducing the number of CT/MRI scans needed over the course of follow-up, with a direct benefit in cost and cumulative radiation exposure for patients who, in the oncologic context, often already undergo multiple imaging studies for other indications.

Practical advantages and limitations

Practical advantages of CEUS include the ability to perform it at the bedside (including in intensive care units, for patients too unstable to transport), near-unlimited repeatability within the same exam (the contrast injection can be repeated within minutes if the first acoustic window is unsatisfactory), generally lower cost than contrast-enhanced CT or MRI, and the absence of radiation and nephrotoxicity discussed earlier. These features make CEUS particularly valuable in patients with renal insufficiency, pregnant patients, children, and patients who need multiple reassessments over a short time interval.

The limitations, however, are real and deserve to be stated clearly. Availability of ultrasound contrast agents and the regulation of their use vary significantly between countries — in the United States, for example, some indications remain off-label or restricted, while in Europe and Asia use has been more broadly established and regulated for longer, including for extra-hepatic indications. This creates variability in accumulated operator experience and in access to the exam depending on the region. CEUS is also operator-dependent, requiring specific training in both image acquisition and interpretation of enhancement patterns, and its acoustic window can be limited by obesity, bowel gas, or the anatomical position of the lesion, just as with conventional ultrasound.

Finally, it is essential to recognize that CEUS does not fully replace CT or MRI in every oncologic staging context: it evaluates one lesion at a time, with a limited field of view, and does not offer the panoramic view of the entire abdomen or chest needed to search for lymphadenopathy, distant metastases, or extensive vascular assessment in a single exam, as cross-sectional methods do. The role of CEUS, therefore, is complementary — often resolving a focused diagnostic problem left unanswered by an inconclusive CT or MRI — rather than replacing those methods for complete oncologic staging.

In summary, CEUS has established itself as a real-time perfusion tool with robust evidence in the liver (LI-RADS), a well-established role in the kidney and in post-EVAR vascular follow-up, and promising, though still maturing, applications in the prostate and carotid plaque. Its greatest value lies in offering, without radiation or renal risk, a dynamic and immediate answer that complements — and often resolves — what CT and MRI leave open, provided the exam is performed and interpreted by professionals with specific training in the technique.